Zotarolimus-Versus Sirolimus-Versus PacliTaxel-Eluting Stent for Acute Myocardial Infarction Patients (ZEST-AMI)

This study has been terminated.
(The recruitment rate was much slower than expected.)
Sponsor:
Collaborator:
Cordis Corporation
Information provided by:
CardioVascular Research Foundation, Korea
ClinicalTrials.gov Identifier:
NCT00422565
First received: January 16, 2007
Last updated: January 30, 2009
Last verified: January 2009

January 16, 2007
January 30, 2009
October 2006
September 2008   (final data collection date for primary outcome measure)
The composite of death (all cause-mortality), MI (Q wave and non Q wave) and ischemia-driven target vessel revascularization. [ Time Frame: At 12 months after the index procedure ] [ Designated as safety issue: Yes ]
The composite of death (all cause-mortality), MI (Q wave and non Q wave) and ischemia-clinically driven target vessel revascularization, which is named as target vessel failure (TVF) at 12 months.
Complete list of historical versions of study NCT00422565 on ClinicalTrials.gov Archive Site
  • All-cause Death [ Time Frame: 1 month, 6 month, 1 year and thereafter annaully up to 5 years ] [ Designated as safety issue: Yes ]
  • Cardiac death [ Time Frame: 1 month, 6 month, 1 year and thereafter annaully up to 5 years ] [ Designated as safety issue: Yes ]
  • Recurrent Myocardial infarction [ Time Frame: 1 month, 6 month, 1 year and thereafter annaully up to 5 years ] [ Designated as safety issue: Yes ]
  • Target vessel revascularization (all and ischemia-driven) [ Time Frame: 1 month, 6 month, 1 year and thereafter annaully up to 5 years ] [ Designated as safety issue: No ]
  • Target lesion revascularization (all and ischemia-driven) [ Time Frame: 1 month, 6 month, 1 year and thereafter annaully up to 5 years ] [ Designated as safety issue: No ]
  • Stent thrombosis for the patients [ Time Frame: 1 month, 6 month, 1 year and thereafter annaully up to 5 years ] [ Designated as safety issue: Yes ]
  • Late luminal loss in both in-stent and in-segment [ Time Frame: at 8 month angiographic follow-up ] [ Designated as safety issue: No ]
  • Binary restenosis in both in-stent and in-segment [ Time Frame: at 8 month angiographic follow-up ] [ Designated as safety issue: No ]
  • Procedural success defined as achievement of a final diameter stenosis of <30% by QCA using any percutaneous method, without the occurrence of death, Q wave MI, or repeat revascularization of the target lesion [ Time Frame: during the hospital stay ] [ Designated as safety issue: Yes ]
  • All-cause Death
  • Cardiac death
  • Myocardial infarction
  • Target vessel revascularization (all and ischemia-driven)
  • Target lesion revascularization (all and ischemia-driven)
  • Stent thrombosis for the patients
  • Late luminal loss in both in-stent and in-segment at 8 month angiographic follow-up
  • Binary restenosis in both in-stent and in-segment at 8 month angiographic follow-up
  • Angiographic pattern of restenosis at 8 month angiographic follow-up
  • Procedural success defined as achievement of a final diameter stenosis of <30% by QCA using any percutaneous method, without the occurrence of death, Q wave MI, or repeat revascularization of the target lesion during the hospital stay.
Not Provided
Not Provided
 
Zotarolimus-Versus Sirolimus-Versus PacliTaxel-Eluting Stent for Acute Myocardial Infarction Patients
Comparison of the Efficacy and Safety of Zotarolimus-Eluting Stent Versus Sirolimus-Eluting Stent Versus PacliTaxel-Eluting Stent for Acute Myocardial Infarction Patients

The trial has the following primary objective:

To compare the safety and effectiveness of primary acute MI intervention with ABT 578-eluting balloon expandable stent (Medtronic, Minneapolis, MN) vs. sirolimus-eluting balloon expandable stent (Cordis Johnson & Johnson, Warren, New Jersey) vs. paclitaxel-eluting stent (Taxus Liberte, Boston Scientific).

Previous studies have documented that a slow-release polymeric sirolimus-eluting stent (Cypher, Cordis) and paclitaxel-eluting stent (Taxus, Boston Scientific) reduce neointimal formation and result in decrease of angiographic restenosis and target lesion revascularization at 1-3 years in the multicenter randomized clinical trials RAVEL, SIRIUS, and TAXUS I-VI. From these studies, the two leading drug-eluting stents (DESs) of the Cypher and Taxus have been widely and rapidly accepted as a standard treatment of coronary lesions.

Recently, randomized studies were conducted to reveal different outcomes of the different two DESs. These studies showed that the sirolimus-eluting stent was better than the paclitaxel-eluting stent in terms of lower angiographic restenosis rate or the two DESs were similar in angiographic outcomes. A recent meta-analysis supported results of the former randomized studies. Patients receiving sirolimus-eluting stent had a significantly lower risk of restenosis and target vessel revascularization compared with those receiving paclitaxel-eluting stent.

With a recent approval of new DES, ABT-578-eluting stent (Endeavor, Medtronic, Minneapolis, MN), other comparison studies have been conducted to compare Endeavor ABT-578-eluting stent with the sirolimus-eluting stent and paclitaxel-eluting stent. The ENDEAVOR clinical trials are currently in progress to evaluate a phosphoryl choline (PC)-coated ABT-578-eluting stent for the prevention of restenosis. Angiographic analysis at 4 months in the 100-patient focal de novo lesion ENDEAVOR I feasibility study demonstrated a mean in-stent percent diameter stenosis of approximately 14% and a late lumen loss of 0.3 mm with a low frequency of target lesion revascularization (1%). The clinical outcomes from the ENDEAVOR II (1,197 patients randomized to ABT-578 or bare metal stent) showed superior efficacy of the PC-coated ABT-578-eluting stent than bare-metal stent.

In patients with acute myocardial infraction (MI), routine stent implantation has been shown to have a better procedural success rate and clinical outcome than balloon angioplasty [11]. However, restenosis and vessel reocclusion remain major challenges limiting the long-term success of percutaneous treatment.

In a clinical study of 400 patients with stent implantation in acute MI, angiographic restenosis occurred in 31%, considerably more than expected for patients with stable coronary disease. There is very little information available as to the efficacy and long-term safety of DES in acute MI. The results from the several registry and randomized trials (Cypher-AMI, Typhoon, PASSION) demonstrated the short-term or long-term safety and efficacy of DES compared to BMS.

The incomplete evidence to date is that implantation of SES in patients with Acute MI is safe and effective more than BMS and results of implantation of PES are at variance with the results of the BMS. However, up to date, there are randomized trials to compare the efficacy and safety among commonly used DES (zotarolimus- vs. sirolimus- vs. paclitaxel-eluting stents) for the treatment of acute MI patients. The results of large randomized trials and larger registries will allow us to make evidence-based decisions about which stent to use in patients with acute MI. Therefore, we designed a randomized, controlled, partially blinded trial comparing the safety and efficacy of the zotarolimus vs. sirolimus vs. paclitaxel stents in acute MI patients undergoing percutaneous coronary intervention.

Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Myocardial Infarction
  • Device: Endeavor, Medtronic
    Zotarolimus-eluting stent
    Other Name: Zotarolimus-eluting stent
  • Device: Cypher, Cordis
    Sirolimus-eluting stent
    Other Name: Sirolimus-eluting stent
  • Device: Taxus Liberte, Boston Scientific
    Paclitaxel-eluting stent
    Other Name: Paclitaxel-eluting stent
  • Experimental: Endeavor
    Zotarolimus-eluting stent
    Intervention: Device: Endeavor, Medtronic
  • Active Comparator: Cypher
    Sirolimus-eluting stent
    Intervention: Device: Cypher, Cordis
  • Active Comparator: Taxus
    Paclitaxel-eluting stent
    Intervention: Device: Taxus Liberte, Boston Scientific
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
328
September 2008
September 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. The patient must be at least 18 years of age.
  2. Culprit de novo lesion in a native coronary artery with significant stenosis (>50% by visual estimate) eligible for stent implantation (no limitation on stent length)
  3. Prolonged, continuous (≥ 20 min) chest pain despite nitrate and: (1) at least 1mm ST-segment elevation in at least 2 leads or reciprocal ST-segment depression ≥ 2 contiguous precordial leads, or (2) newly developed left bundle branch block
  4. Symptoms < 12 hours
  5. The patient or guardian agrees to the study protocol and the schedule of clinical and angiographic follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethical Committee of the respective clinical site.

Exclusion Criteria:

  1. The patient has a known hypersensitivity or contraindication to any of the following medications:

    • Heparin
    • Aspirin
    • Both Clopidogrel and TIclopidine
    • Sirolimus, paclitaxel, ABT 578
    • Stainless steel and/or
    • Contrast media (patients with documented sensitivity to contrast which can be effectively pre-medicated with steroids and diphenhydramine [e.g. rash] may be enrolled. Patients with true anaphylaxis to prior contrast media, however, should not be enrolled).
  2. Systemic (intravenous) Sirolimus, paclitaxel or ABT-578 use within 12 months.
  3. Female of childbearing potential, unless a recent pregnancy test is negative, who possibly plan to become pregnant any time after enrollment into this study.
  4. History of bleeding diathesis or known coagulopathy (including heparin-induced thrombocytopenia), or will refuse blood transfusions.
  5. Fibrinolytic therapy for current MI treatment
  6. Previous coronary intervention on target vessel
  7. Non-cardiac co-morbid conditions are present with life expectancy <1 year or that may result in protocol non-compliance (per site investigator's medical judgment).
  8. Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period.
  9. Previously documented LVEF <30%.
  10. Evident cardiogenic shock before randomization
  11. Patients with left main stem stenosis (>50% by visual estimate)
  12. Severe calcification or tortuosity
  13. Multi-vessel disease with non-culprit vessel requiring bypass surgery
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Korea, Republic of
 
NCT00422565
2006-0137
Yes
Seung-Jung Park, Asan Medical Center
CardioVascular Research Foundation, Korea
Cordis Corporation
Principal Investigator: Seung-Jung Park, MD, PhD Department of Medicine, Asan Medical Center, University of Ulsan College of Medicine
CardioVascular Research Foundation, Korea
January 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP